ABCMdb

PMID: 15910652

Owen A, Chandler B, Back DJ
The implications of P-glycoprotein in HIV: friend or foe?
Fundam Clin Pharmacol. 2005 Jun;19(3):283-96., [PubMed]

Sentences

No. Mutations Sentence Comment

83 ABCB1 p.Ser400Asn Increased in TT homozygotesCD4 response Singh et al. (2003) [84] 71 (11% Caucasian; 23% Hispanic; 66% Black) 8 weeks NFV, EFV NFV level Lower in CC homozygotes CD4 response No difference Petersen et al. (2003) [85] 142 (Caucasian, African-American or Hispanic) 48 weeks NFV, EFV CD4 response No difference Verstuyft et al. (2003) [86] 76 (Not given) 72 weeks IDV Drug level No difference Maher et al. (2003) [87] 12 (Caucasian) 1 dose IDV Cmax Higher in CC homozygotes Brumme et al. (2003) [88] 461 (Predominantly Caucasian and Aboriginal) 192 weeks Not Specified CD4 response No difference Nasi et al. (2003) [89] 149 (Caucasian) 24 weeks Not specified CD4 and virological response to PIs No difference CD4 response to NNRTIs Higher in TT homozygotes Ifergan et al. (2003) [90] 137 (Caucasian) N/A N/A HIV-1 infectivity No difference Chandler et al. (2003) [44] 16 (Caucasian) N/A N/A P-gp inducibility No difference Haas et al. (2003) [91] 31 (84% Caucasian) 24 weeks RTV Ctrough No difference CD4 and virological response No difference Winzer et al. (2003) [92] 67 (Caucasian) LPV 53 weeks; EFV 105 weeks LPV, EFV LPV Ctrough No difference EFV C12 No difference Bleiber et al. (2004) [53] 411 (Predominantly Caucasian) 8 years Not specified CD4+ response No difference van der Ende et al. (2004) [93] 186 (61% Caucasian; 30% Black) 12 weeks NVP Drug levels No difference Hulgan et al. (2004) [94] 205 (72% Caucasian; 28% Black) During routine care Not specified P-gp efflux activity Lower in TT homozygotes CD4 and virological response No difference Anderson et al. (2004) [95] 33 (79% Caucasian; 21% Black) 72 weeks IDV CL/F No difference Owen et al. (2004) [96] 108 (>80% Caucasian) 48 weeks IDV, SQV, RTV Ctrough No difference serine to asparagine at position 400 of the protein. Login to comment